MYGN
MYRIAD GENETICS INC
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$6.35
−4.80%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 0.75x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 2.00x
- Price / sales
- 0.75x
- Price / cash flow
- 78.88x
Enterprise value
- Enterprise value
- $702.7M
- EV / sales
- 0.87x
- EV / EBITDA
- -15.55x
- EV / EBIT
- -7.13x
- Market cap
- $607.4M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026